237 related articles for article (PubMed ID: 8425205)
1. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.
Montgomery AM; De Clerck YA; Langley KE; Reisfeld RA; Mueller BM
Cancer Res; 1993 Feb; 53(3):693-700. PubMed ID: 8425205
[TBL] [Abstract][Full Text] [Related]
2. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
Lim YT; Sugiura Y; Laug WE; Sun B; Garcia A; DeClerck YA
J Cell Physiol; 1996 May; 167(2):333-40. PubMed ID: 8613475
[TBL] [Abstract][Full Text] [Related]
3. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
[TBL] [Abstract][Full Text] [Related]
4. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
5. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
6. Melanocyte mediated paracrine induction of extracellular matrix degrading proteases in squamous cell carcinoma cells.
Borchers AH; Sanders LA; Powell MB; Bowden GT
Exp Cell Res; 1997 Feb; 231(1):61-5. PubMed ID: 9056412
[TBL] [Abstract][Full Text] [Related]
7. Studies on the effects of laminin, E-8 fragment of laminin and synthetic laminin peptides PA22-2 and YIGSR on matrix metalloproteinases and tissue inhibitor of metalloproteinase expression.
Mackay AR; Gomez DE; Nason AM; Thorgeirsson UP
Lab Invest; 1994 Jun; 70(6):800-6. PubMed ID: 8015284
[TBL] [Abstract][Full Text] [Related]
8. Membrane type I-matrix metalloproteinase-mediated degradation of type I collagen by oral squamous cell carcinoma cells.
Aznavoorian S; Moore BA; Alexander-Lister LD; Hallit SL; Windsor LJ; Engler JA
Cancer Res; 2001 Aug; 61(16):6264-75. PubMed ID: 11507081
[TBL] [Abstract][Full Text] [Related]
9. Cumulative influence of matrix metalloproteinase-1 and -2 in the migration of melanoma cells within three-dimensional type I collagen lattices.
Ntayi C; Lorimier S; Berthier-Vergnes O; Hornebeck W; Bernard P
Exp Cell Res; 2001 Oct; 270(1):110-8. PubMed ID: 11597133
[TBL] [Abstract][Full Text] [Related]
10. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
11. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.
Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF
Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Webber MM; Waghray A
Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042
[TBL] [Abstract][Full Text] [Related]
13. Leukemic cells (HL-60) produce a novel extracellular matrix-degrading proteinase that is not inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs).
Dittmann KH; Lottspeich F; Ries C; Petrides PE
Exp Hematol; 1995 Feb; 23(2):155-60. PubMed ID: 7828672
[TBL] [Abstract][Full Text] [Related]
14. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells.
Meade-Tollin LC; Way D; Witte MH
Acta Histochem; 1999 Jul; 101(3):305-16. PubMed ID: 10443293
[TBL] [Abstract][Full Text] [Related]
15. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
Pei XH; Nakanishi Y; Takayama K; Bai F; Hara N
Br J Cancer; 1999 Jan; 79(1):40-6. PubMed ID: 10408691
[TBL] [Abstract][Full Text] [Related]
17. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
Lijnen HR; Silence J; Lemmens G; Frederix L; Collen D
Thromb Haemost; 1998 Jun; 79(6):1171-6. PubMed ID: 9657444
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation.
Teesalu T; Masson R; Basset P; Blasi F; Talarico D
Dev Dyn; 1999 Mar; 214(3):248-58. PubMed ID: 10090151
[TBL] [Abstract][Full Text] [Related]
19. Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity.
Lunter PC; van Kilsdonk JW; van Beek H; Cornelissen IM; Bergers M; Willems PH; van Muijen GN; Swart GW
Cancer Res; 2005 Oct; 65(19):8801-8. PubMed ID: 16204050
[TBL] [Abstract][Full Text] [Related]
20. Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography.
Kurschat P; Wickenhauser C; Groth W; Krieg T; Mauch C
J Pathol; 2002 Jun; 197(2):179-87. PubMed ID: 12015741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
